Flexible sigmoidoscopy versus faecal occult blood testing for colorectal cancer screening in asymptomatic individuals

Cochrane Database of Systematic Reviews

Volumn 2013, Issue 9, 2013, Pages

  Holme, Oyvind ^a   Bretthauer, Michael ^b   Fretheim, Atle ^c   Odgaard Jensen, Jan ^c   Hoff, Geir ^d  

^a Sorlandet Hospital Kristiansand   (Norway)

^b UNIVERSITY OF OSLO   (Norway)

^c NORWEGIAN KNOWLEDGE CENTRE FOR THE HEALTH SERVICES   (Norway)

^d TELEMARK HOSPITAL   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

GUAIAC; DIAGNOSTIC AGENT; DYES, REAGENTS, INDICATORS, MARKERS AND BUFFERS;

ADVERSE OUTCOME; ALL CAUSE MORTALITY; ASYMPTOMATIC DISEASE; BAYES THEOREM; CANCER INCIDENCE; CANCER MORTALITY; CANCER RISK; CANCER SCREENING; CANCER STAGING; CLINICAL EFFECTIVENESS; CLINICAL OUTCOME; COLONOSCOPY; COLORECTAL CANCER; COMPARATIVE EFFECTIVENESS; EVIDENCE BASED MEDICINE; HUMAN; INTERMETHOD COMPARISON; META ANALYSIS; OCCULT BLOOD TEST; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REPEAT PROCEDURE; REVIEW; RISK ASSESSMENT; SIGMOIDOSCOPY; SYSTEMATIC REVIEW; COLON TUMOR; MORTALITY; OCCULT BLOOD; RECTUM TUMOR;

COLONIC NEOPLASMS; COLONOSCOPY; GUAIAC; HUMANS; INDICATORS AND REAGENTS; OCCULT BLOOD; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECTAL NEOPLASMS; SIGMOIDOSCOPY;

EID: 84890939875     PISSN: None     EISSN: 1469493X     Source Type: Journal    
DOI: 10.1002/14651858.CD009259.pub2     Document Type: Review

References (72)

1. Atkin WS, Cook CF, Cuzick J, Edwards R, Northover JM, Wardle J. Single flexible sigmoidoscopy screening to prevent colorectal cancer: baseline findings of a UK multicentre randomised trial. Lancet 2002;359(9314):1291-300. [PUBMED: 11965274]
2. Atkin WS, Edwards R, Kralj-Hans I, Wooldrage K, Hart AR, Northover JM, et al.Once-only flexible sigmoidoscopy screening in prevention of colorectal cancer: a multicentre randomised controlled trial. Lancet 2010;375(9726):1624-33. [PUBMED: 20430429]
3. Gondal G, Grotmol T, Hofstad B, Bretthauer M, Eide TJ, Hoff G. The Norwegian Colorectal Cancer Prevention (NORCCAP) screening study: baseline findings and implementations for clinical work-up in age groups 50-64 years. Scandinavian Journal of Gastroenterology 2003;38(6):635-42. [PUBMED: 12825872]
4. Hardcastle JD, Chamberlain JO, Robinson MH, Moss SM, Amar SS, Balfour TW, et al.Randomised controlled trial of faecal-occult-blood screening for colorectal cancer. Lancet 1996;348(9040):1472-7. [PUBMED: 8942775]
5. Hoff G, Sauar J, Vatn MH, Larsen S, Langmark F, Moen IE, et al.Polypectomy of adenomas in the prevention of colorectal cancer: 10 years' follow-up of the Telemark Polyp Study I. A prospective, controlled population study. Scandinavian Journal of Gastroenterology 1996;31(10):1006-10. [PUBMED: 8898422]
6. Hoff G, Thiis-Evensen E, Grotmol T, Sauar J, Vatn MH, Moen IE. Do undesirable effects of screening affect all-cause mortality in flexible sigmoidoscopy programmes? Experience from the Telemark Polyp Study 1983-1996. European Journal of Cancer Prevention 2001;10(2):131-7. [PUBMED: 11330453]
7. Hoff G, Grotmol T, Skovlund E, Bretthauer M. Risk of colorectal cancer seven years after flexible sigmoidoscopy screening: randomised controlled trial. BMJ (Clinical research ed.) 2009;338:b1846. [PUBMED: 19483252]
8. Jorgensen OD, Kronborg O, Fenger C. A randomised study of screening for colorectal cancer using faecal occult blood testing: results after 13 years and seven biennial screening rounds. Gut 2002;50(1):29-32. [PUBMED: 11772963]
9. Kewenter J, Brevinge H, Engaras B, Haglind E, Ahren C. Results of screening, rescreening, and follow-up in a prospective randomized study for detection of colorectal cancer by fecal occult blood testing. Results for 68, 308 subjects. Scandinavian Journal of Gastroenterology 1994;29(5):468-73. [PUBMED: 8036464]
10. Kewenter J, Brevinge H. Endoscopic and surgical complications of work-up in screening for colorectal cancer. Diseases of the Colon and Rectum 1996;39(6):676-80. [PUBMED: 8646956]
11. Kronborg O, Fenger C, Olsen J, Jorgensen OD, Sondergaard O. Randomised study of screening for colorectal cancer with faecal-occult-blood test. Lancet 1996;348(9040):1467-71. [PUBMED: 8942774]
12. Kronborg O, Jorgensen OD, Fenger C, Rasmussen M. Randomized study of biennial screening with a faecal occult blood test: results after nine screening rounds. Scandinavian Journal of Gastroenterology 2004;39(9):846-51. [PUBMED: 15513382]
13. Larsen IK, Grotmol T, Bretthauer M, Gondal G, Huppertz-Hauss G, Hofstad B, et al.Continuous evaluation of patient satisfaction in endoscopy centres. Scandinavian Journal of Gastroenterology 2002;37(7):850-5. [PUBMED: 12190102]
14. Larsen IK, Grotmol T, Almendingen K, Hoff G. Impact of colorectal cancer screening on future lifestyle choices: a three-year randomized controlled trial. Clinical Gastroenterology and Hepatology 2007;5(4):477-83. [PUBMED: 17363335]
15. Lindholm E, Berglund B, Kewenter J, Haglind E. Worry associated with screening for colorectal carcinomas. Scandinavian Journal of Gastroenterology 1997;32(3):238-45. [PUBMED: 9085461]
16. Lindholm E, Brevinge H, Haglind E. Survival benefit in a randomized clinical trial of faecal occult blood screening for colorectal cancer. The British Journal of Surgery 2008;95(8):1029-36. [PUBMED: 18563785]
17. Mandel JS, Bond JH, Church TR, Snover DC, Bradley GM, Schuman LM, et al.Reducing mortality from colorectal cancer by screening for fecal occult blood. Minnesota Colon Cancer Control Study. The New England Journal of Medicine 1993;328(19):1365-71. [PUBMED: 8474513]
18. Mandel JS, Church TR, Ederer F, Bond JH. Colorectal cancer mortality: effectiveness of biennial screening for fecal occult blood. Journal of the National Cancer Institute 1999;91(5):434-7. [PUBMED: 10070942]
19. Mandel JS, Church TR, Bond JH, Ederer F, Geisser MS, Mongin SJ, et al.The effect of fecal occult-blood screening on the incidence of colorectal cancer. The New England Journal of Medicine 2000;343(22):1603-7. [PUBMED: 11096167]
20. Miles A, Wardle J, McCaffery K, Williamson S, Atkin W. The effects of colorectal cancer screening on health attitudes and practices. Cancer Epidemiology, Biomarkers & Prevention 2003;12(7):651-5. [PUBMED: 12869406]
21. Parker MA, Robinson MH, Scholefield JH, Hardcastle JD. Psychiatric morbidity and screening for colorectal cancer. Journal of Medical Screening 2002;9(1):7-10. [PUBMED: 11943790]
22. Robinson MH, Hardcastle JD, Moss SM, Amar SS, Chamberlain JO, Armitage NC, et al.The risks of screening: data from the Nottingham randomised controlled trial of faecal occult blood screening for colorectal cancer. Gut 1999;45(4):588-92. [PUBMED: 10486370]
23. Schoen RE, Weissfeld JL, Bowen NJ, Switzer G, Baum A. Patient satisfaction with screening flexible sigmoidoscopy. Archives of Internal Medicine 2000;160(12):1790-6. [PUBMED: 10871972]
24. Schoen R, Pinsky P, Weissfield J, Yokochi L, Church T, Laiyemo A, et al.Colorectal-cancer incidence and mortality with screening flexible sigmoidoscopy. The New England Journal of Medicine 2012;366:2345-57. [PUBMED: 22612596]
25. Scholefield JH, Moss S, Sufi F, Mangham CM, Hardcastle JD. Effect of faecal occult blood screening on mortality from colorectal cancer: results from a randomised controlled trial. Gut 2002;50(6):840-4. [PUBMED: 12010887]
26. Scholefield JH, Moss SM, Mangham CM, Whynes DK, Hardcastle JD. Nottingham trial of faecal occult blood testing for colorectal cancer: a 20-year follow-up. Gut 2012;61(7):1036-40. [PUBMED: 22052062]
27. Segnan N, Senore C, Andreoni B, Aste H, Bonelli L, Crosta C, et al.Baseline findings of the Italian multicenter randomized controlled trial of "once-only sigmoidoscopy"--SCORE. Journal of the National Cancer Institute 2002;94(23):1763-72. [PUBMED: 12464648]
28. Segnan N, Armaroli P, Bonelli L, Risio M, Sciallero S, Zappa M, et al.Once-only sigmoidoscopy in colorectal cancer screening: Follow-up findings of the Italian randomized controlled trial--SCORE. Journal of the National Cancer Institute 2011;103(17):1310-22. [PUBMED: 21852264]
29. Taylor T, Williamson S, Wardle J, Borrill J, Sutton S, Atkin W. Acceptability of flexible sigmoidoscopy screening in older adults in the United Kingdom. Journal of Medical Screening 2000;7(1):38-45. [PUBMED: 10807146]
30. Thiis-Evensen E, Hoff GS, Sauar J, Langmark F, Majak BM, Vatn MH. Population-based surveillance by colonoscopy: effect on the incidence of colorectal cancer. Telemark Polyp Study I. Scandinavian Journal of Gastroenterology 1999;34(4):414-20. [PUBMED: 10365903]
31. Wardle J, Williamson S, Sutton S, Biran A, McCaffery K, Cuzick J, et al.Psychological impact of colorectal cancer screening. Health Psychology 2003;22(1):54-9. [PUBMED: 12558202]
32. Berry DP, Clarke P, Hardcastle JD, Vellacott KD. Randomized trial of the addition of flexible sigmoidoscopy to faecal occult blood testing for colorectal neoplasia population screening. The British Journal of Surgery 1997;84(9):1274-6. [PUBMED: 9313712]
33. Brevinge H, Lindholm E, Buntzen S, Kewenter J. Screening for colorectal neoplasia with faecal occult blood testing compared with flexible sigmoidoscopy directly in a 55-56 years' old population. International Journal of Colorectal Disease 1997;12(5):291-5. [PUBMED: 9401844]
34. Denis B, Gendre I, Aman F, Ribstein F, Maurin P, Perrin P. Colorectal cancer screening with the addition of flexible sigmoidoscopy to guaiac-based faecal occult blood testing: a French population-based controlled study (Wintzenheim trial). European Journal of Cancer 2009;45(18):3282-90. [PUBMED: 19665368]
35. Faivre J, Dancourt V, Lejeune C, Tazi MA, Lamour J, Gerard D, et al.Reduction in colorectal cancer mortality by fecal occult blood screening in a French controlled study. Gastroenterology 2004;126(7):1674-80. [PUBMED: 15188160]
36. Li S, Nie Z, Li N, Li J, Zhang P, Yang Z, et al.Colorectal cancer screening for the natural population of Beijing with sequential fecal occult blood test: a multicenter study. Chinese Medical Journal 2003;116(2):200-2. [PUBMED: 12775229]
37. Rasmussen M, Kronborg O, Fenger C, Jorgensen OD. Possible advantages and drawbacks of adding flexible sigmoidoscopy to hemoccult-II in screening for colorectal cancer. A randomized study. Scandinavian Journal of Gastroenterology 1999;34(1):73-8. [PUBMED: 10048736]
38. Selby JV, Friedman GD, Collen MF. Sigmoidoscopy and mortality from colorectal cancer: the Kaiser Permanente Multiphasic Evaluation Study. Journal of Clinical Epidemiology 1988;41(5):427-34. [PUBMED: 3367172]
39. Thiis-Evensen E, Hoff GS, Sauar J, Majak BM, Vatn MH. The effect of attending a flexible sigmoidoscopic screening program on the prevalence of colorectal adenomas at 13-year follow-up. The American Journal of Gastroenterology 2001;96(6):1901-7. [PUBMED: 11419846]
40. Winawer SJ, Flehinger BJ, Schottenfeld D, Miller DG. Screening for colorectal cancer with fecal occult blood testing and sigmoidoscopy. Journal of the National Cancer Institute 1993;85(16):1311-8. [PUBMED: 8340943]
41. Zheng S, Chen K, Liu X, Ma X, Yu H, Chen K, et al.Cluster randomization trial of sequence mass screening for colorectal cancer. Diseases of the Colon and Rectum 2003;46(1):51-8. [PUBMED: 12544522]
42. Paimela H, Malila N, Palva T, Hakulinen T, Vertio H, Jarvinen H. Early detection of colorectal cancer with faecal occult blood test screening. The British Journal of Surgery 2010;97(10):1567-71. [PUBMED: 20603855]
43. Anderson JC, Alpern Z, Messina CR, Lane B, Hubbard P, Grimson R, et al.Predictors of proximal neoplasia in patients without distal adenomatous pathology. The American Journal of Gastroenterology 2004;99(3):472-7. [PUBMED: 15056088]
44. Atkin WS, Morson BC, Cuzick J. Long-term risk of colorectal cancer after excision of rectosigmoid adenomas. The New England Journal of Medicine 1992;326(10):658-62. [PUBMED: 1736104]
45. Baxter NN, Goldwasser MA, Paszat LF, Saskin R, Urbach DR, Rabeneck L. Association of colonoscopy and death from colorectal cancer. Annals of Internal Medicine 2009;150(1):1-8. [PUBMED: 19075198]
46. Bland JM, Kerry SM. Statistics notes. Trials randomised in clusters. BMJ 1997;300:600.
47. Brenner H, Hoffmeister M, Arndt V, Stegmaier C, Altenhofen L, Haug U. Protection from right-and left-sided colorectal neoplasms after colonoscopy: population-based study. Journal of the National Cancer Institute 2010;102(2):89-95. [PUBMED: 20042716]
48. Brenner H, Chang-Claude J, Seiler CM, Rickert A, Hoffmeister M. Protection from colorectal cancer after colonoscopy: a population-based, case-control study. Annals of Internal Medicine 2011;154(1):22-30. [PUBMED: 21200035]
49. Divine GW, Brown JT, Frazer LM. The unit of analysis error in studies about physicians' patient care behavior. Journal of General Internal Medicine 1992;4:623-9.
50. Ferlay J, Parkin DM, Steliarova-Foucher E. Estimates of cancer incidence and mortality in Europe in 2008. European Journal of Cancer 2010;46(4):765-81. [PUBMED: 20116997]
51. Gervaz P, Bucher P, Morel P. Two colons-two cancers: paradigm shift and clinical implications. Journal of Surgical Oncology 2004;88(4):261-6. [PUBMED: 15565587]
52. Gulliford MC, Ukoumunne OC, Chinn S. Components of variance and intra class correlations for the design of community-based surveys and intervention studies: data from the Health Survey for England 1994. American Journal of Epidemiology 1999;149:876-83.
53. Hewitson P, Glasziou P, Irwig L, Towler B, Watson E. Screening for colorectal cancer using the faecal occult blood test, Hemoccult. Cochrane Database of Systematic Reviews 2007, Issue 1. [DOI: 10.1002/14651858.CD001216.pub2; PUBMED: 17253456]
54. Higgins JPT, Green S (editors). Cochrane handbook of Systematic reviews of Intervention Version 5.0.2 [updated September 2009]. The Cochrane Collaboration. Available from www.cochrane-handbook.org. Wiley/Blackwell, 2008.
55. Hol L, van Leerdam ME, van Ballegooijen M, van Vuuren AJ, van Dekken H, Reijerink JC, et al.Screening for colorectal cancer: randomised trial comparing guaiac-based and immunochemical faecal occult blood testing and flexible sigmoidoscopy. Gut 2010;59(1):62-8. [PUBMED: 19671542]
56. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics, 2009. CA: a Cancer Journal for Clinicians 2009;59(4):225-49. [PUBMED: 19474385]
57. Lang CA, Ransohoff DF. Fecal occult blood screening for colorectal cancer. Is mortality reduced by chance selection for screening colonoscopy?. JAMA 1994;271(13):1011-3. [PUBMED: 8139058]
58. Lansdorp-Vogelaar I, Knudsen AB, Brenner H. Cost-effectiveness of colorectal cancer screening -an overview. Best Practice & Research. Clinical Gastroenterology 2010;24(4):439-49. [PUBMED: 20833348]
59. Levin B, Lieberman DA, McFarland B, Andrews KS, Brooks D, Bond J, et al.Screening and surveillance for the early detection of colorectal cancer and adenomatous polyps, 2008: a joint guideline from the American Cancer Society, the US Multi-Society Task Force on Colorectal Cancer, and the American College of Radiology. Gastroenterology 2008;134(5):1570-95. [PUBMED: 18384785]
60. Muto T, Bussey HJ, Morson BC. The evolution of cancer of the colon and rectum. Cancer 1975;36(6):2251-70. [PUBMED: 1203876]
61. Newcomb PA, Storer BE, Morimoto LM, Templeton A, Potter JD. Long-term efficacy of sigmoidoscopy in the reduction of colorectal cancer incidence. Journal of the National Cancer Institute 2003;95(8):622-5. [PUBMED: 12697855]
62. Peters JL, Sutton AJ, Jones DR, Abrams KR, Rushton L. Comparison of two methods to detect publication bias in meta-analysis. JAMA 2006;295:676-80.
63. Regula J, Rupinski M, Kraszewska E, Polkowski M, Pachlewski J, Orlowska J, et al.Colonoscopy in colorectal-cancer screening for detection of advanced neoplasia. The New England Journal of Medicine 2006;355(18):1863-72. [PUBMED: 17079760]
64. Ries L, Melbert D, Krapcho M, Stinchcomb D, Howlader N, Horner M, et al.SEER Cancer Statistics Review, 1975-2005. http://seer.cancer.gov/csr/1975-2005/.
65. Salanti G, Higgins JP, Ades AE, Ioannidis JPA. Evaluation of networks of randomized trials. Statistical Methods in Medical Research 2007;17:279-301.
66. Schünemann HJ, Oxman AD, Vist GE, Higgins JPT, Deeks JJ, Glasziou P, Guyatt GH. Chapter 12: Interpreteing results and drawing conclusions. In: Higgins JPT, Green S editor(s). Cochrane Handbook for Systematic Reviews of Interventions. Chichester (UK): John Wiley & Sons, 2008.
67. Segnan N, Senore C, Andreoni B, Arrigoni A, Bisanti L, Cardelli A, et al.SCORE2 Working Group-Italy. Randomized trial of different screening strategies for colorectal cancer: patient response and detection rates. Journal of the National Cancer Institute 2005;97(5):347-57. [Pubmed: 15741571]
68. Selby JV, Friedman GD, Quesenberry CP Jr, Weiss NS. A case-control study of screening sigmoidoscopy and mortality from colorectal cancer. The New England Journal of Medicine 1992;326(10):653-7. [PUBMED: 1736103]
69. Simpson NK, Johnson CC, Ogden SL, Gamito E, Trocky N, McGuire C, et al.Recruitment strategies in the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial: the first six years. Controlled Clinical Trials 2000;21(6 Suppl):356S-78S. [PUBMED: 11189688]
70. Stewart-Brown S, Farmer A. Screening could seriously damage your health. BMJ (Clinical research ed.) 1997; Vol. 314, issue 7080:533-4. [PUBMED: 9055702]
71. van Dam L, Kuipers EJ, van Leerdam ME. Performance improvements of stool-based screening tests. Best Practice & Research. Clinical Gastroenterology 2010;24(4):479-92. [PUBMED: 20833351]
72. Vogelstein B, Fearon ER, Hamilton SR, Kern SE, Preisinger AC, Leppert M, et al.Genetic alterations during colorectal-tumor development. The New England Journal of Medicine 1988;319(9):525-32. [PUBMED: 2841597]